These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 6139453)

  • 1. Elimination from the circulation of cats of 6-keto-prostaglandin E1 compared with prostaglandins E2 and I2.
    Förstermann U; Neufang B
    J Pharm Pharmacol; 1983 Nov; 35(11):724-8. PubMed ID: 6139453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypotensive response to prostacyclin and 6-keto-PGE1 following hepatectomy in the rat.
    Van Dam J; Stinger RB; Penhos JC; Ramwell PW; Kot PA
    Proc Soc Exp Biol Med; 1984 Sep; 176(4):438-42. PubMed ID: 6379654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2.
    Spannhake EW; Levin JL; Hyman AL; Kadowitz PJ
    Prostaglandins; 1981 Feb; 21(2):267-75. PubMed ID: 7012934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose intrarenal infusions of PGE2, PGI2, and 6-keto-PGE1 vasodilate the in vivo rat kidney.
    Jackson EK; Heidemann HT; Branch RA; Gerkens JF
    Circ Res; 1982 Jul; 51(1):67-72. PubMed ID: 7044603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of intravitreal and topical prostaglandins on intraocular inflammation.
    Kulkarni PS; Srinivasan BD
    Invest Ophthalmol Vis Sci; 1982 Sep; 23(3):383-92. PubMed ID: 7050005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.
    Jackson EK; Herzer WA; Zimmerman JB; Branch RA; Oates JA; Gerkens JF
    J Pharmacol Exp Ther; 1981 Jan; 216(1):24-7. PubMed ID: 7005428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Keto-prostaglandin E1 is a potent coronary vasodilator and stimulates a vagal reflex in dogs.
    Panzenbeck MJ; Hintze TH; Kaley G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):814-9. PubMed ID: 3075239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.
    Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prostacyclin on the fetal pulmonary circulation.
    Cassin S; Winikor I; Tod M; Philips J; Frisinger J; Jordan J; Gibbs C
    Pediatr Pharmacol (New York); 1981; 1(3):197-207. PubMed ID: 7050867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the prostacyclin products, 6-keto prostaglandin E1 and 6-keto prostaglandin F1 alpha, on bone resorption in vitro.
    Neuman SD; Raisz LG
    Prostaglandins Leukot Med; 1984 Jul; 15(1):103-8. PubMed ID: 6382342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Keto-prostaglandin E1-stimulated bone resorption in organ culture.
    Dewhirst FE
    Calcif Tissue Int; 1984 Jul; 36(4):380-3. PubMed ID: 6435837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental vascular responses to 6-keto-prostaglandin E1 in the near-term sheep.
    Schwartz DB; Phernetton TM; Stock MK; Rankin JH
    Am J Obstet Gynecol; 1983 Feb; 145(4):406-10. PubMed ID: 6337494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
    Hyman AL; Kadowitz PJ
    J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pressor and depressor actions of prostanoids in the intact human fetoplacental vascular bed.
    Howard RB; Hosokawa T; Maguire MH
    Prostaglandins Leukot Med; 1986 Mar; 21(3):323-30. PubMed ID: 3517885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pulmonary, hepatic and renal extraction of PGI2 and 6-keto-PGE1.
    Tsunoda S; Jackson EK; Branch RA; Gerkens JF
    Eur J Pharmacol; 1982 Jan; 77(2-3):147-51. PubMed ID: 7037431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U; Stahl T; Hackenthal E
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective antagonism of the systemic vasodepressor response to PGE1 by d,1-11, 15-bisdeoxy PGE1.
    Stinger RB; Fitzpatrick TM; Van Dam J; Ramwell PW; Kot PA
    Prostaglandins; 1980 Feb; 19(2):213-20. PubMed ID: 6992223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics.
    Bothwell W; Verburg M; Wynalda M; Daniels EG; Fitzpatrick FA
    J Pharmacol Exp Ther; 1982 Feb; 220(2):229-35. PubMed ID: 6948952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
    Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.